WO1998046227A1 - Composition for treating pain - Google Patents
Composition for treating pain Download PDFInfo
- Publication number
- WO1998046227A1 WO1998046227A1 PCT/US1998/007293 US9807293W WO9846227A1 WO 1998046227 A1 WO1998046227 A1 WO 1998046227A1 US 9807293 W US9807293 W US 9807293W WO 9846227 A1 WO9846227 A1 WO 9846227A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- compound
- synergistic analgesic
- analgesic
- group
- Prior art date
Links
- IQWCBYSUUOFOMF-ZRDIBKRKSA-N CO/N=C(/C1C(CC2)CCN2C1)\C#N Chemical compound CO/N=C(/C1C(CC2)CCN2C1)\C#N IQWCBYSUUOFOMF-ZRDIBKRKSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Definitions
- the present invention relates to a method for treating pain using cyano-oxi e compounds.
- the method of this invention provides a method for treating pain using compounds which were previously disclosed for use in the treatment of Alzheimer's Disease.
- the method of this invention provide the clinician with another treatment option for the treatment of pain.
- the compounds used in the presently claimed method appear to have an acceptable side effect profile while providing surprising analgesic activity.
- the presently claimed composition can provide a synergistic effect for the treatment of pain.
- the present invention provides a composition for the treatment of pain comprising a Compound I:
- r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;
- R 2 is a group OR 4 , where R 4 is C ⁇ _ 4 alkyl, C 2 - 4 alkenyl, C 2 - 4 alkynyl, a group OCOR 5 where R 5 is hydrogen or
- R 4 ; and R 3 is CN; or a pharmaceutically acceptable salt or solvate thereof; and one or more Synergistic Analgesics in a weight ratio of Compound I to Synergistic Analgesic of from about one part Compound I to from about one (1) to about one thousand (1000) parts Synergistic Analgesic.
- a preferred composition is a weight ratio of Compound I to Synergistic Analgesic of from about one (1) part Compound I to from about one (1) to about hundred (100) parts Synergistic Analgesic.
- An especially preferred ratio is from about one part Compound I (1) to from about one (1) to about thirty (30) parts Synergistic Analgesic.
- a further preferred ratio may be from about one part Compound I to from about one (1) to about ten (10) parts Synergistic Analgesic.
- a final preferred ratio may be from about one (1) part Compound I to from about one (1) to about three (3) parts Synergistic Analgesic.
- Non-Steroidal Antiinflammatory Agents include, but are in no way limited to salicylates such as aspirin.
- NSAIDS Non-Steroidal Antiinflammatory Agents
- Another preferred group of NSAIDS include, but are not limited to, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, eclofenamate, ketoprofen, piroxicam, flurbiprofen, and diclofenac.
- Particularly preferred NSAIDS are selected from the group consisting of ibuprofen, and naproxen.
- Another particularly preferred NSAIDS is aspirin.
- the invention further provides a composition for treating pain comprising Compound I or a pharmaceutically acceptable salt or solvate thereof and one or more Synergistic Analgesic in a weight ratio of Compound I to Synergistic Analgesic of from about one part Compound I to from about one (1) to about one thousand (1000) parts Synergistic Analgesic.
- the present invention provides a method for treating pain comprising administering to a patient in need thereof, an analgesic composition comprising a Compound I:
- R 1 represents:
- r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;
- R 2 is a group OR 4 , where R 4 is C 1 - 4 alkyl, C 2 -4 alkenyl, C 2 - 4 alkynyl, a group OCOR 5 where R 5 is hydrogen or
- R 4 ; and R 3 is CN; or a pharmaceutically acceptable salt or solvate thereof; and one or more Synergistic Analgesics in a weight ratio of Compound I to Synergistic Analgesic of from about one part Compound I to from about one (1) to about one thousand (1000) parts Synergistic Analgesic.
- R 1 represents:
- r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;
- R 2 is a group OR 4 , where R 4 is C ⁇ _ 4 alkyl, C 2 -4 alkenyl, C 2 - 4 alkynyl, a group OCOR 5 where R 5 is hydrogen or
- R 4 ; and R 3 is CN; or a pharmaceutically acceptable salt or solvate thereof.
- a particularly preferred Compound I is of the formula II:
- An especially preferred compound is known as SB202026.
- Synergistic Analgesic shall mean a compound; or a pharmaceutically acceptable salt thereof, that is known to the artisan to have clinical analgesic activity.
- Synergistic Analgesic shall include, but is in no way limited to, NSAIDS, opioid compounds, and alpha adrenergic compounds.
- Drugs Useful in the Treatment of Pain shall also encompass classical analgesic agents known to the artisan. See for example, Goodman and Gillman, The Pharmacological Basis of Therapeutics, 5 th edition, Macmillan Publishing Co., 1975, pp 325-358, and similar references commonly consulted by the skilled artisan.
- the term shall include, for example, Tylenol #3, tricyclic antidepressants (for example desipramine, imipramine, amytriptiline, nortriptiline) , anticonvulsants (for example, carbamazepine, gatapentine, valproate) , and serotonin reuptake inhibitors (for example, fluoxetine, paroxetine, citalopra , sertraline) , mixed serotonin-norepinephrine reuptake inhibitors (for example venlafaxine, duloxetine) , serotonin receptor agonists and antagonists, cholinergic (muscarinic and nicotinic) analgesics, and neurokinin antagonists.
- tricyclic antidepressants for example desipramine, imipramine, amytriptiline, nortriptiline
- anticonvulsants for example, carbamazepine, gatapentine, valproate
- Especially preferred Drugs Useful in the Treatment of Pain can be selected from the group consisting of tricyclic antidepressants, anticonvulsants, and serotonin-norepinephrine reuptake inhibitors.
- alpha-adrenergic compounds represents a compound having central alpha- adrenergic receptor activity.
- the most preferred central alpha-adrenergic active compound is clonidine or a pharmaceutically acceptable salt thereof having the chemical name: 2- (2, 6-dichlorophenylamino) -2-imidazoline.
- New alpha adrenergic active agents are undergoing pharmacolgoical development.
- the present invention encompasses all such agents which function as a central alpha-adrenergic active compound.
- Clonidine is known to be useful for treating hypertension. see Physicians' Desk Reference, 45th Ed. (1991) p. 673.
- opioid or "opioid compounds”, as used herein, has the meaning commonly associated with the term by the skilled artisan.
- Preferred opioid compounds are selected from the group consisting of morphine, codeine, meperidine, methadone, propoxyphene, levorphanol, hydromorphone, oxymorphone, oxycodone, brompton's cocktail, pentazocine, butorphanol, nabuphine, and buprenorphine .
- NSAIDS represents a nonsteroidal anti-inflammatory drug which can be identified as such by the skilled artisan.
- the Merck Manual, 16th Edition, Merck Research Laboratories (1990) pp 1308 - 1309 provide well known examples of NSAIDS.
- the term is intended to include, but is not limited to salicylates such as aspirin.
- the term includes, but is not limited to, indomethacin, ibuprofen, naproxen, fenoprofen, tolmetin, sulindac, meclofenamate, ketoprofen, piroxicam, flurbiprofen, and diclofenac.
- Especially preferred NSAIDS include ibuprofen, and naproxen.
- NSAID is aspirin.
- Particularly preferred NSAIDS include aspirin and ibuprofen.
- the salicylates may include acetylsalicylic acid, sodium acetylsalicylic acid, calcium acetylsalicylic acid, salicylic acid, and sodium salicylate.
- the term NSAIDS shall refer to any compound acting as a nonsteroidal antiinflammatory agent. Applicants appreciate that new NSAIDS may be in development, and the present invention contemplates a synergistic composition comprising such new agents with Compound I as well.
- the term "animal” shall refer to a vertebrate animal. Most preferably, the vertebrate animal is a mammal. As used herein, the term “mammal” shall refer to the Mammalia class of higher vertebrates. The term “mammal” includes, but is not limited to, a human. The term “treating” as used herein includes prophylaxis of the named condition or amelioration or elimination of the condition once it has been established.
- alkyl refers to the number of carbon atoms indicated; however, when no number is specified, the term refers to C ⁇ -6 alkyl.
- the alkyl may be linear or branched unless specified.
- alkynyl has its accepted meaning; however, if the number of carbon atoms are unspecified, it refers to C 2 - 1 0 alkynyl.
- the alkynyl group may be linear or branched unless specified.
- analgesic dose represents an amount of compound necessary to prevent or treat a human susceptible to or suffering from pain following administration to such human.
- the active compounds are effective over a wide dosage range. For example, dosages per day will normally fall within the range of about 0.005 to about 500 mg/kg of body weight. In the treatment of adult humans, the range of about 0.05 to about 100 mg/kg, in single or divided doses, is preferred.
- the amount of the composition actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.
- the present compounds are preferably administered orally to humans susceptible to or suffering from pain, the compounds may also be administered by a variety of other routes such as the transder al, parenterally, subcutaneous, intranasal, intramuscular and intravenous routes.
- Such formulations may be designed to provide delayed or controlled release using formulation techniques which are known in the art.
- a preferred composition is a weight ratio of Compound I to Synergistic Analgesic of from about one (1) part Compound I to from about one (1) to about one hundred (100) parts Synergistic Analgesic.
- An especially preferred ratio is from about one part Compound I to from about one (1) to about thirty (30) parts Synergistic Analgesic.
- a further preferred ratio may be from about one part Compound I to from about one (1) to about ten (10) parts Synergistic Analgesic.
- a final preferred ratio may be from about one (1) part Compound I to from about one (1) to about three (3) parts Synergistic Analgesic.
- treating includes prophylaxis of a physical and/or mental condition or amelioration or elimination of the developed condition once it has been established or alleviation of the characteristic symptoms of such condition.
- pain shall refer to all types of pain.
- the term shall refer to chronic pains, such as neuropathic pain, and post-operative pain, chronic lower back pain, cluster headaches, herpes neuralgia, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting from burns, including sunburn, post partum pain, migraine, angina pain, and genitourinary tract- related pain including cystitis, the term shall also preferredly refer to nociceptive pain or nociception.
- Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically-acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are known to the skilled artisan.
- compositions suitable for internal administration contain from about one half (0.5) milligrams to about 600 milligrams of active ingredient per unit.
- the active ingredient will ordinarily be present in an amount of from about 0.5% to about 95% by weight based on the total weight of the composition.
- the daily dosage can be such that the active ingredient is administered at a daily dosage of from about 0.2 mg/kg to about 500 mg/kg of body weight Compound I and from about 0.6 to about 200 mg/kg of acetaminophen .
- compositions include Compound I and one or more Synergistic Analgesics, associated with a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
- a pharmaceutically acceptable excipient which may be a carrier, or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper, or other container.
- the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container.
- the carrier When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound.
- the active compound can be adsorbed on a granular solid container for example in a sachet.
- suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone.
- the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents.
- the formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
- the pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.
- injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
- Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
- Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch.
- a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
- compositions of this invention are dispensed in unit form comprising from about 0.1 to about 500 mg in a pharmaceutically acceptable carrier per unit dosage.
- compositions of this invention may be suitable for administration to an animal.
- animals include both domestic animals, for example livestock, laboratory animals, and household pets, and non-domestic animals such as wildlife. More preferably, the animal is a vertebrate.
- a composition of this invention shall be administered to a mammal. It is especially preferred that the animal is a domestic mammal or a human. For such domestic animal purposes, a composition of this invention may be administered as a feed additive. The most preferred mammal is a human.
- Nociceptive pain model Nociceptive pain model :
- Acetic acid-induced writhing A standard procedure for detecting and comparing the analgesic activity of different classes of analgesic drugs for which there is a good correlation with human analgesic activity is the prevention of acetic acid-induced writhing in mice.
- Mice are subcutaneously administered various doses of the claimed composition and are injected injected intraperitoneally with acetic acid (0.5% solution, 10 ml/kg) 5 min prior to a designated observation period.
- acetic acid (0.5% solution, 10 ml/kg
- a "writhe" is indicated by whole body stretching or contraction of the abdomen during the observation period beginning 5 min after receiving the acetic acid. Inhibition of writhing behavior is demonstrative of analgesic activity.
- Sciatic nerve ligation model Rats are anesthetized and a nerve ligation procedure performed. The common sciatic nerve is exposed and 4 ligatures tied loosely around it with about 1 mm spacing. One day to 10 weeks after surgery, the nociceptive testing is performed. Responses to noxious heat are determined by placing the rats in a chamber with a clear glass floor and aiming at the plantar surface of the affected foot a radiant heat source from beneath the floor. Increased latency to withdraw the hindpaw is demonstrative of analgesic activity. Responses to normally innocuous mechanical stimuli is determined by placing the rats in a chamber with a screen floor and stimulating the plantar surface of the hind paw with graduated von Frey hairs which are calibrated by the grams of force required to bend them.
- Rats with sciatic nerve ligation respond to lower grams of mechanical stimulation by reflexive withdrawal of the foot than unoperated rats.
- This response to stimuli which are normally innocuous is termed allodynia.
- Increases in the grams of mechanical force required to produce foot withdrawal is demonstrative of antiallodynic activity.
- Bennett, G.J. and Xie, Y.-K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107.
- Rats are anesthetized and when there is a loss of spontaneous movement the rats are injected subcutaneously in the dorsal surface of the hindpaw with 50 ul of 5% formalin solution using a 30 gauge needle. Rats are then individually placed in an open Plexiglas chamber for observation, and within a maximum interval of 1 to 2 min, the animal displays recovery from anesthesia with spontaneous activity and normal motor function. Pain behavior is quantified by periodically counting the incidents of spontaneous flinching/shaking of the injected paw. The flinches are counted for 1-min periods at 1- to 2- , 5- to 6- and 5min intervals during the interval from 10 to 60 min. Inhibition of the pain behavior is demonstrative of an analgesic activity.
- mice Male mice are fasted for 16- 22 hours and weighed. Mice weighing from about 18-22 grams at the time of testing are used for the following studies. All mice are dosed sequentially by the oral route with suspensions of a composition of this invention. Doses are coded using a code unknown to the observer.
- a stock suspension of the test composition is prepared by mixing the active ingredients with about 40 mL of an aqueous vehicle containing about 2% Tween 80 (R) , a pharmacological dispersant and containing 100% polysorbate 80, and 1% by weight Methocel (R) MC powder, and containing 100% methylcellulose, in distilled water. The mixture may be sonicated for about 10 to about 15 seconds using an ultrasound sytem. All dosing suspensions are prepared by dilution of the stock suspension with Methocel/Tween 80. All suspensions are used within two hours of preparation.
- Mouse Writhing Test An accepted standard for detecting and comparing the analgesic activity of different classes of analgesic compounds for which there is a good correlation with human analgesic activity is the prevention of phenyl-p-benzoquinone induced writhing in mice. [H. Blumberg et al . Proc. Soc. Exp. biol. Med., 118, 763-766 (1965) ] .
- mice treated with various doses of Compound I, composition or vehicle are injected intraperitoneally with a standard challenge dose of phenyl-p-benzoquinone 5 minutes prior to a designated observation period.
- the pheyl-p-benzoquinone is prepared as about 0.1 mg/ml solution in about 5% by volume of ethanol in water.
- the writhing dose is 1.25 mg/kg injected at a volume of about 0.25ml/10g.
- a "writhe" is indicated by whole body stretching or contracting of the abdomen during an observation period beginning about five minutes after the phenyl-p-benzoquinone dose.
- the solid line connecting the ED50 dosages of Compound I (alone) and Synergistic Analgesic as claimed herein (alone) represents the "ED50 addition line" which indicates the expected location of the ED50's for Compound I and classical analagesic combinations if simple additivity were to describe their combined effects.
- the 95% confidence range for the ED50 addition line is shown by the area between the broken lines above and below the ED50 addition line.
- compositions comprised of a Compound I and one or more Synergistic Analgesics provides a statistically significant synergistic analgesic effect.
- Preferred Compound I compounds are of Formula II, hereinabove .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98915497A EP1007041A4 (en) | 1997-04-11 | 1998-04-10 | Composition for treating pain |
JP54412698A JP2002503224A (en) | 1997-04-11 | 1998-04-10 | Composition for treating pain |
AU69669/98A AU6966998A (en) | 1997-04-11 | 1998-04-10 | Composition for treating pain |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4357497P | 1997-04-11 | 1997-04-11 | |
US60/043,574 | 1997-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998046227A1 true WO1998046227A1 (en) | 1998-10-22 |
Family
ID=21927854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/007293 WO1998046227A1 (en) | 1997-04-11 | 1998-04-10 | Composition for treating pain |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1007041A4 (en) |
JP (1) | JP2002503224A (en) |
AU (1) | AU6966998A (en) |
WO (1) | WO1998046227A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000028980A2 (en) * | 1998-11-13 | 2000-05-25 | Eli Lilly And Company | Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain |
US6559171B1 (en) | 1999-06-04 | 2003-05-06 | Eli Lilly And Company | 7-oxo-2-azabicyclo[2.2.1]heptanes as selective muscarinic receptor antagonist |
DE102004011392A1 (en) * | 2004-01-13 | 2005-08-04 | Grünenthal GmbH | Weak to moderate opioids or combinations of these opioids with antidepressants for the treatment of depression, anxiety disorders and pain |
US7317011B2 (en) | 1999-07-01 | 2008-01-08 | Pharmacia & Upjohn | Method of treating peripheral neuropathy |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0428170D0 (en) * | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Mono and Combination Therapy |
US20080275131A1 (en) * | 2007-04-30 | 2008-11-06 | Adolor Corporation | Compositions of (-)-e-10-oh-nt and methods for their synthesis and use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5418240A (en) * | 1990-08-21 | 1995-05-23 | Novo Nordisk A/S | Heterocyclic compounds and their preparation and use |
US5545740A (en) * | 1992-02-20 | 1996-08-13 | Smithkline Beecham, P.L.C. | Nitrosation process |
US5677313A (en) * | 1993-08-19 | 1997-10-14 | Novo Nordisk A/S | Antipsychotic method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA199800533A1 (en) * | 1995-12-07 | 1999-02-25 | Эли Лилли Энд Компани | COMPOSITION FOR THE TREATMENT OF PAIN |
-
1998
- 1998-04-10 WO PCT/US1998/007293 patent/WO1998046227A1/en not_active Application Discontinuation
- 1998-04-10 AU AU69669/98A patent/AU6966998A/en not_active Abandoned
- 1998-04-10 EP EP98915497A patent/EP1007041A4/en not_active Withdrawn
- 1998-04-10 JP JP54412698A patent/JP2002503224A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5418240A (en) * | 1990-08-21 | 1995-05-23 | Novo Nordisk A/S | Heterocyclic compounds and their preparation and use |
US5545740A (en) * | 1992-02-20 | 1996-08-13 | Smithkline Beecham, P.L.C. | Nitrosation process |
US5677313A (en) * | 1993-08-19 | 1997-10-14 | Novo Nordisk A/S | Antipsychotic method |
Non-Patent Citations (1)
Title |
---|
See also references of EP1007041A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000028980A2 (en) * | 1998-11-13 | 2000-05-25 | Eli Lilly And Company | Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain |
WO2000028980A3 (en) * | 1998-11-13 | 2000-07-27 | Lilly Co Eli | Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain |
US6559171B1 (en) | 1999-06-04 | 2003-05-06 | Eli Lilly And Company | 7-oxo-2-azabicyclo[2.2.1]heptanes as selective muscarinic receptor antagonist |
US7317011B2 (en) | 1999-07-01 | 2008-01-08 | Pharmacia & Upjohn | Method of treating peripheral neuropathy |
DE102004011392A1 (en) * | 2004-01-13 | 2005-08-04 | Grünenthal GmbH | Weak to moderate opioids or combinations of these opioids with antidepressants for the treatment of depression, anxiety disorders and pain |
Also Published As
Publication number | Publication date |
---|---|
AU6966998A (en) | 1998-11-11 |
EP1007041A1 (en) | 2000-06-14 |
EP1007041A4 (en) | 2001-03-07 |
JP2002503224A (en) | 2002-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6444665B1 (en) | Method for treating pain | |
US5945416A (en) | Method for treating pain | |
JPH0733331B2 (en) | Analgesic and anti-inflammatory compositions comprising diphenhydramines | |
CN102302492A (en) | Methods and compositions for the treatment of neuropathic pain | |
BRPI0610663A2 (en) | therapeutic use of nefopam and its analogs | |
EP1007041A1 (en) | Composition for treating pain | |
WO1998046601A1 (en) | Composition for treating pain | |
JP2000501711A (en) | How to treat pain | |
WO1997020556A9 (en) | Method for treating pain | |
AU705031B2 (en) | Composition for treating pain | |
CZ2006623A3 (en) | Combination of deramciclane and opioids as analgesics | |
PT1610785E (en) | Pharmaceutical combination for the treatment of spasticity and/or pain | |
BRPI0613281A2 (en) | therapeutic combination containing an nmda receptor blocker and a narcotic analgesic substance | |
MXPA98004519A (en) | Composition to treat do | |
BARTON | Glossary of medical terms | |
TW200906406A (en) | Use of a compound that is a neurokinin A NK2 receptor antagonist for the preparation of medicaments for use in the prevention and treatment of sexual dysfunctions | |
BG109702A (en) | Combination of deramciclane and opioids as analgesics | |
KR20000004965A (en) | Method for treating pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998915497 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 544126 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09403063 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998915497 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998915497 Country of ref document: EP |